Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure (polypharmacy phenogroups and heart failure subgroups outcomes)

31 August 2025 (09:15 - 10:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ahmad Aboughalia

Hamad General Hospital, Doha (Qatar)

6 More presentations in this session

Presentation thumbnail

Multicenter study on the effect of Mavacamten on pulmonary artery systolic pressure derived from echo-doppler in obstructive hypertrophic cardiomyopathy

Doctor M. Gegenava (Tbilisi, GE)

Abstract Slides Video

Presentation thumbnail

Comparison of characteristics and outcomes of patients with obstructive vs. non-obstructive hypertrophic cardiomyopathy in a cohort from a referral center in colombia

Doctor J. Orozco Burbano (Medellin, CO)

Abstract Slides Video

Presentation thumbnail

Outcomes of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in Japan

Doctor T. Yamaguchi (Tokyo, JP)

Abstract Slides Video

Presentation thumbnail

Genetic, echocardiographic and clinical determinants of mitral valve abnormalities in hypertrophic cardiomyopathy

Miss H. Panholzer (Graz, AT)

Abstract Slides Video

Presentation thumbnail

Common pathophysiological mechanism of SAM and mitral regurgitation in HOCM

Associate Professor Z. Wang (Hangzhou, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Left ventricular outflow tract obstruction

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET

You may be interested in

Congress Presentation

Polypharmacy as an independent predictor of heart failure hospitalization and mortality in HFrEF patients

Congress Session

Advances in heart failure detection and therapy

Congress Session

Insights from recent HFrEF trials 2

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources